Terms: = Head and neck cancer AND STK11, LKB1, 6794, ENSG00000118046, Q15831, PJS AND Treatment
36 results:
1. Oridonin inhibited epithelial-mesenchymal transition of laryngeal carcinoma by positively regulating lkb1/AMPK signaling.
Kou B; Shi Y; Zhou Z; Yun Y; Wu Q; Zhou J; Liu W
Int J Med Sci; 2024; 21(4):623-632. PubMed ID: 38464825
[TBL] [Abstract] [Full Text] [Related]
2. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
Besse B; Pons-Tostivint E; Park K; Hartl S; Forde PM; Hochmair MJ; Awad MM; Thomas M; Goss G; Wheatley-Price P; Shepherd FA; Florescu M; Cheema P; Chu QSC; Kim SW; Morgensztern D; Johnson ML; Cousin S; Kim DW; Moskovitz MT; Vicente D; Aronson B; Hobson R; Ambrose HJ; Khosla S; Reddy A; Russell DL; Keddar MR; Conway JP; Barrett JC; Dean E; Kumar R; Dressman M; Jewsbury PJ; Iyer S; Barry ST; Cosaert J; Heymach JV
Nat Med; 2024 Mar; 30(3):716-729. PubMed ID: 38351187
[TBL] [Abstract] [Full Text] [Related]
3. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
[TBL] [Abstract] [Full Text] [Related]
4. Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma.
Boiarsky D; Lydon CA; Chambers ES; Sholl LM; Nishino M; Skoulidis F; Heymach JV; Luo J; Awad MA; Janne PA; Van Allen EM; Barbie DA; Vokes NI
Ann Oncol; 2023 Jul; 34(7):589-604. PubMed ID: 37121400
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer.
Hong L; Aminu M; Li S; Lu X; Petranovic M; Saad MB; Chen P; Qin K; Varghese S; Rinsurongkawong W; Rinsurongkawong V; Spelman A; Elamin YY; Negrao MV; Skoulidis F; Gay CM; Cascone T; Gandhi SJ; Lin SH; Lee PP; Carter BW; Wu CC; Antonoff MB; Sepesi B; Lewis J; Gibbons DL; Vaporciyan AA; Le X; Jack Lee J; Roy-Chowdhuri S; Routbort MJ; Gainor JF; Heymach JV; Lou Y; Wu J; Zhang J; Vokes NI
Nat Commun; 2023 Feb; 14(1):695. PubMed ID: 36755027
[TBL] [Abstract] [Full Text] [Related]
6. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung cancer Reveals
De B; Farooqi AS; Mitchell KG; Ludmir EB; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee JJ; Swisher SG; Gibbons DL; Zhang J; Le X; Elamin YY; Gomez DR; Ning MS; Lin SH; Liao Z; Chang JY; Vaporciyan AA; Heymach JV; Antonoff MB; Gandhi SJ
JCO Precis Oncol; 2023 Jan; 7():e2200540. PubMed ID: 36716413
[TBL] [Abstract] [Full Text] [Related]
7. Over than three-year follow-up results of thermal ablation for papillary thyroid carcinoma: A systematic review and meta-analysis.
Xue J; Teng D; Wang H
Front Endocrinol (Lausanne); 2022; 13():971038. PubMed ID: 36353232
[TBL] [Abstract] [Full Text] [Related]
8. Immunotherapy Mechanism of Esophageal Squamous Cell Carcinoma with the Effect of stk11/AMPK Signaling Pathway.
Xia Y; Wang P; Ye Y; Zhang S; Sun G; Xu J; Han G
Biomed Res Int; 2022; 2022():8636527. PubMed ID: 35463992
[TBL] [Abstract] [Full Text] [Related]
9. Enhanced Vulnerability of lkb1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado.
Galan-Cobo A; Stellrecht CM; Yilmaz E; Yang C; Qian Y; Qu X; Akhter I; Ayres ML; Fan Y; Tong P; Diao L; Ding J; Giri U; Gudikote J; Nilsson M; Wierda WG; Wang J; Skoulidis F; Minna JD; Gandhi V; Heymach JV
Mol Cancer Res; 2022 Feb; 20(2):280-292. PubMed ID: 34654720
[TBL] [Abstract] [Full Text] [Related]
10.
Jiménez-Mora E; Gallego B; Díaz-Gago S; Lasa M; Baquero P; Chiloeches A
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34204950
[TBL] [Abstract] [Full Text] [Related]
11.
Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV
Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404
[TBL] [Abstract] [Full Text] [Related]
12. Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with
Jhaveri K; Chang MT; Juric D; Saura C; Gambardella V; Melnyk A; Patel MR; Ribrag V; Ma CX; Aljumaily R; Bedard PL; Sachdev JC; Dunn L; Won H; Bond J; Jones S; Savage HM; Scaltriti M; Wilson TR; Wei MC; Hyman DM
Clin Cancer Res; 2021 Jan; 27(2):447-459. PubMed ID: 33148674
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic implication of proteomic profiles in head and neck squamous cell carcinoma.
Wu D; Gong P; Zeng Q; Zhang W; Xie F; Zhou X
Clin Chim Acta; 2020 Oct; 509():304-309. PubMed ID: 32569632
[TBL] [Abstract] [Full Text] [Related]
14. STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.
Della Corte CM; Sen T; Gay CM; Ramkumar K; Diao L; Cardnell RJ; Rodriguez BL; Stewart CA; Papadimitrakopoulou VA; Gibson L; Fradette JJ; Wang Q; Fan Y; Peng DH; Negrao MV; Wistuba II; Fujimoto J; Solis Soto LM; Behrens C; Skoulidis F; Heymach JV; Wang J; Gibbons DL; Byers LA
J Thorac Oncol; 2020 May; 15(5):777-791. PubMed ID: 32068166
[TBL] [Abstract] [Full Text] [Related]
15. Characterization of novel genetic alterations in salivary gland secretory carcinoma.
Na K; Hernandez-Prera JC; Lim JY; Woo HY; Yoon SO
Mod Pathol; 2020 Apr; 33(4):541-550. PubMed ID: 31822803
[TBL] [Abstract] [Full Text] [Related]
16. Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation.
Jin Y; Bao H; Le X; Fan X; Tang M; Shi X; Zhao J; Yan J; Xu Y; Quek K; Elamin YY; Zhang J; Futreal PA; Wistuba II; Heymach JV; Lou G; Shao L; He Q; Lin C; Wu X; Shao YW; Wang X; He J; Chen Y; Stebbing J; Chen M; Zhang J; Yu X
Oncogene; 2020 Feb; 39(9):1846-1859. PubMed ID: 31754213
[TBL] [Abstract] [Full Text] [Related]
17. Genetic alterations in human papillomavirus-associated oropharyngeal squamous cell carcinoma of patients with treatment failure.
Reder H; Wagner S; Gamerdinger U; Sandmann S; Wuerdemann N; Braeuninger A; Dugas M; Gattenloehner S; Klussmann JP; Wittekindt C
Oral Oncol; 2019 Jun; 93():59-65. PubMed ID: 31109697
[TBL] [Abstract] [Full Text] [Related]
18. Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung cancer.
Kadara H; Sivakumar S; Jakubek Y; San Lucas FA; Lang W; McDowell T; Weber Z; Behrens C; Davies GE; Kalhor N; Moran C; El-Zein R; Mehran R; Swisher SG; Wang J; Zhang J; Fujimoto J; Fowler J; Heymach JV; Dubinett S; Spira AE; Ehli EA; Wistuba II; Scheet P
Am J Respir Crit Care Med; 2019 Sep; 200(6):742-750. PubMed ID: 30896962
[No Abstract] [Full Text] [Related]
19. PD-L1 Expression, Tumor Mutational Burden, and cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung cancer.
Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
[TBL] [Abstract] [Full Text] [Related]
20. andrographolide inhibits proliferation and induces apoptosis of nasopharyngeal carcinoma cell line C666-1 through lkb1-AMPK-dependent signaling pathways.
Wu B; Chen X; Zhou Y; Hu P; Wu D; Zheng G; Cai Y
Pharmazie; 2018 Oct; 73(10):594-597. PubMed ID: 30223924
[TBL] [Abstract] [Full Text] [Related]
[Next]
